GeneDx Plans to Add Long-Read Whole Genome Sequencing for Rare Disease Testing
The phenotype-driven testing approach aims to detect structural variants and repeat expansions, with an early access program launching by year-end.
The phenotype-driven testing approach aims to detect structural variants and repeat expansions, with an early access program launching by year-end.
In a study of 229 patients, an AI-based liquid biopsy matched magnetic resonance elastography in identifying patients with fibrosis stages associated with eligibility for approved MASH treatments.
The Beckman Coulter assay delivers results in as little as 15 minutes on existing immunoassay analyzers, potentially helping clinicians make faster treatment decisions.
The expanded partnership deploys the cloud-based HALO AP platform across enterprise laboratories to support emerging biomarker workflows and ADC pipeline diagnostics.
Powered by Tribun Health's CaloPix software, the platform connects pathology with radiology and cardiology imaging systems to support diagnostic workflows and collaboration across healthcare networks.
Screen retention errors can misassign patient glucose results in electronic records, leading to one reported injury and a planned software update.
Curiox Biosystems has expanded its commercial leadership team and established a Strategic Advisory Board to support broader adoption of its centrifuge-free Pluto Workstations for automated flow cytometry sample preparation.
A Mayo Clinic study of nearly 50,000 adults found many carriers of sickle cell and beta-thalassemia traits were not identified in electronic health records, highlighting gaps in current documentation practices.
China’s NMPA has approved Quanterix and Innovita’s HD-X and SR-X immunoassay platforms and four blood-based neurology biomarker tests, expanding access to Alzheimer’s diagnostics in the Chinese clinical lab market.
The new 5987A system is designed to improve laboratory efficiency by identifying potential instrument problems before they disrupt testing.
Genefluence's near-patient test identifies UTI-causing bacteria and antibiotic resistance genes in approximately one hour, potentially helping clinicians make faster treatment decisions.
The new platform offers custom panel manufacturing in as little as one day to support development of tumor-informed MRD assays.
Researchers identified blood levels of a brain injury biomarker that could help clinicians determine which patients need additional evaluation within 24 hours of trauma.
A multicenter study from Johns Hopkins Medicine found that an FDA-cleared rapid urine assay detected 92% of invasive aspergillosis cases, offering results within hours and supporting faster, noninvasive diagnosis in clinical labs.